StockNews.com Upgrades Repligen (NASDAQ:RGEN) to “Hold”

StockNews.com upgraded shares of Repligen (NASDAQ:RGEN) from a sell rating to a hold rating in a research report report published on Friday morning.

Several other equities analysts have also issued reports on the company. Wells Fargo & Company assumed coverage on Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective for the company. Wolfe Research began coverage on Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Benchmark reaffirmed a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research report on Thursday, September 26th. Finally, UBS Group decreased their target price on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Price Performance

Repligen stock opened at $146.06 on Friday. The firm has a market capitalization of $8.18 billion, a P/E ratio of -394.59, a PEG ratio of 4.29 and a beta of 0.96. Repligen has a 1 year low of $113.50 and a 1 year high of $211.13. The business has a 50-day moving average of $140.26 and a 200-day moving average of $143.12. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the previous year, the company earned $0.23 EPS. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. On average, equities analysts anticipate that Repligen will post 1.52 EPS for the current year.

Insiders Place Their Bets

In related news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The trade was a 13.70 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in RGEN. Champlain Investment Partners LLC increased its holdings in shares of Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after acquiring an additional 850,345 shares during the last quarter. Thrivent Financial for Lutherans grew its holdings in Repligen by 240.5% in the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock valued at $75,866,000 after buying an additional 425,061 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after buying an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC grew its holdings in Repligen by 26.7% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after buying an additional 199,322 shares in the last quarter. Finally, DF Dent & Co. Inc. grew its holdings in Repligen by 31.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after buying an additional 139,615 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.